Hematology & Medical Biology & Internal Medicine & Family Medicine
Megathrombocytes (large platelets)
Megathrombocytes—also called giant platelets or large platelets—are abnormally large platelets (diameter >4–5 µm, sometimes comparable to or larger than erythrocytes of 7–8 µm) visible on peripheral blood smears. Normal platelets measure 2–3 µm in diameter and have a mean platelet volume (MPV) of 7.5–12 fL on automated blood counts. Megathrombocytes are produced by megakaryocytes in the bone marrow during accelerated thrombopoietic activity—the released platelets are younger, larger, and more functionally active. Their presence on a blood smear is therefore a sign of increased platelet production, indicating that the bone marrow is compensating for accelerated peripheral destruction or consumption of platelets—most often in the context of thrombocytopenia. The presence of megathrombocytes should be interpreted in conjunction with the platelet count, clinical context, the rest of the blood smear (other cell lines), and biochemical data. The main causes of megathrombocytes are: thrombocytopenias with increased production (ITP—immune thrombocytopenic purpura + microangiopathies + hypersplenism + drug-induced thrombocytopenias) + constitutional thrombocytopathies with giant platelets (Bernard-Soulier syndrome—characteristic giant platelets + familial giant platelets) + certain blood disorders (myelodysplasia + AML + myeloproliferations).
Platelet Physiology, Mechanisms, and Classification
- Physiology of thrombopoiesis and mechanisms of megathrombocyte formation: Normal thrombopoiesis: Megakaryocytes (giant bone marrow cells) produce platelets through fragmentation of their cytoplasmic extensions (proplatelets) -> one megakaryocyte produces 2,000–3,000 platelets -> thrombopoietin (TPO) is the main regulator of platelet production -> TPO produced by the liver -> binds to the c-Mpl receptor on megakaryocytes + platelets (negative feedback) -> normal platelet lifespan: 7–10 days + normal platelet count reference values: 150–400 × 10⁹/L -> mechanisms of giant platelet formation: increased stimulation of thrombopoiesis -> megakaryocytes produce larger, younger, and more active platelets -> giant platelets = reticulated «young platelets» (containing residual RNA) -> indicate regeneration -> their presence with thrombocytopenia -> accelerated production in response to peripheral destruction -> similar to reticulocytosis in anemia + MPV (mean platelet volume): automated parameter that increases with giant platelets -> MPV >12 fL -> suspect giant platelets -> but MPV is influenced by many analytical factors (sampling delay + EDTA + counting method) -> blood smear remains the reference examination to confirm and qualify giant platelets -> giant platelets vs pseudo-thrombocytopenia EDTA: platelet aggregates on smear + falsely low platelet count -> citrate tube + heparin tube -> correct before interpreting
- Classification of giant platelets by context and causes: Classification of megathrombocytes by mechanism and context: Megathrombocytes with thrombocytopenia — increased destruction or consumption (most frequent mechanism): ITP (Immune Thrombocytopenic Purpura): anti-platelet autoantibodies (anti-GPIIb/IIIa + anti-GPIb/IX) → splenic destruction of opsonized platelets → stimulated megakaryocytes → young and large platelets + thrombotic microangiopathies (TTP + HUS + HELLP + DIC): massive platelet consumption → accelerated production → megathrombocytes + drug-induced thrombocytopenia → hypersplenism (splenic sequestration) → megathrombocytes without thrombocytopenia or with reactive thrombocytosis: viral infection + recovery after chemotherapy + rebound thrombocytosis → constitutional megathrombocytes (hereditary giant platelets): Bernard-Soulier syndrome (BSS): autosomal recessive + GPIb-IX-V mutation → characteristic giant platelets (sometimes as large as erythrocytes — «ghost» platelets) + moderate thrombocytopenia + very prolonged bleeding time + absence of aggregation with ristocetin → genetic diagnosis + absence of thrombotic risk → autosomal dominant familial giant platelets: MYH9 (myosin heavy chain 9) → May-Hegglin syndrome + Fechtner syndrome + Sebastian syndrome + Epstein syndrome → giant platelets + Döhle bodies in neutrophils → Glanzmann thrombasthenia: normal-sized platelets but severely functionally deficient (absent GPIIb/IIIa) → no megathrombocytes → megathrombocytes with other hematological abnormalities (myelodysplasia + myelofibrosis + AML + CML): abnormal production → dysplastic + dysfunctional + hyper- or hypogranular platelets
Etiological diagnosis and management
| Etiology / Context | Diagnostic approach and treatment | References and recommendations |
|---|---|---|
| Diagnostic approach for giant platelets Blood smear confirmed — CBC platelets — MPV — reticulocytes — LDH haptoglobin hemolysis — Coombs — anti-platelet antibodies — bone marrow aspirate — hematologist expert smear — EDTA pseudothrombocytopenia — citrate tube — targeted etiological workup |
Diagnostic approach to the discovery of giant platelets on a blood smear: Step 1 — Confirm and qualify on blood smear: blood smear examined by an expert technician → platelet size + morphology (granules + color + clumping) + abnormalities of other cell lines (schistocytes → microangiopathy + hypersegmented neutrophils → megaloblastosis + blasts → malignant hematologic disorder + Döhle bodies in neutrophils → MYH9 syndrome) → Step 2 — Rule out EDTA pseudothrombocytopenia: if very low platelet count on automated analyzer but patient is asymptomatic → repeat on citrate tube or heparin tube → if normal platelet count → EDTA pseudothrombocytopenia (no treatment) → Step 3 — Etiological workup guided by clinical context: if thrombocytopenia + giant platelets → probable peripheral destruction or consumption → complete blood count + blood smear + LDH + haptoglobin + indirect bilirubin (hemolysis → microangiopathy) + direct Coombs test + anti-platelet antibodies → reticulocytes → if isolated thrombocytopenia without hemolysis → probable ITP → dosage of anti-GPIIb/IIIa + anti-GPIb antibodies → if fever + hemolysis + renal failure + thrombocytopenia + schistocytes → TTP or HUS → emergency → ADAMTS13 + shiga toxins → if giant platelets + abnormalities of other cell lines (pancytopenia + refractory anemia + dysplasia) → myelodysplastic syndrome → bone marrow aspiration + karyotyping + NGS → bone marrow aspiration and biopsy (BMB): indicated if: severe thrombocytopenia of uncertain etiology + abnormalities of other cell lines + suspected hematologic malignancy → if isolated giant platelets → suspicion of constitutional syndrome → GPIb-IX-V genotyping (Bernard-Soulier) + MYH9 + coagulation panel + bleeding time (prolonged in Bernard-Soulier) + platelet aggregation tests (absence of ristocetin in Bernard-Soulier) | Gresele 2014 — Platelets: Gigantothrombocytes + Differential Diagnosis → Review + Harrison 2019 — British Journal of Haematology: Hereditary Thrombocytopenia + Diagnosis → Nurden 2008 — Haematologica: Bernard-Soulier Syndrome + Giant Platelets + Diagnosis → Rodeghiero 2009 — Blood (ASH Guidelines): ITP + Diagnosis + Treatment + Swerdlow 2022 — Blood (WHO Classification): Hematologic Malignancies + Platelet Dysplasia + AHOQ (Association des hémato-oncologues du Québec) + INESSS Québec + RAMQ: CBC + Smear + LDH + Haptoglobin + Coombs + Bone Marrow Aspiration → Reimbursed According to Indication |
| Immune thrombocytopenic purpura (ITP) - the most common cause ITP exclusion diagnosis — anti-GPIIb/IIIa — corticosteroids prednisone — IVIG intravenous immunoglobulins — rituximab — thrombopoietin TPO agonists eltrombopag romiplostim — splenectomy — platelet treatment threshold 20 30 — hemorrhage — pregnancy ITP — child ITP self-limited |
ITP (immune thrombocytopenic purpura) — the most common cause of megatrombocytes with thrombocytopenia: definition and pathophysiology: diagnosis of exclusion → isolated thrombocytopenia (<100 × 10⁹/L) + megatrombocytes on smear + no identifiable cause + anti-platelet IgG autoantibodies (anti-GPIIb/IIIa ++ + anti-GPIb/IX) → platelet opsonization → splenic phagocytosis → increased destruction → autoreactive CD4+ T cells stimulate B cells → B cells produce autoantibodies → autoantibodies also inhibit megakaryopoiesis → treatment of ITP — depending on severity and platelet count: first-line treatment (newly diagnosed ITP): prednisone 1 mg/kg/day × 2–4 weeks → then gradual tapering → efficacy: ↑ platelet count in 70–80% of cases → but relapse upon discontinuation in 70% of cases + intravenous immunoglobulin (IVIG) 1 g/kg × 1–2 days: rapid onset (24–48 hours) → especially in cases of hemorrhagic emergency + or imminent surgery + or pregnancy → temporary (4–6 weeks) → anti-D (WinRho) in Rh+ patients who have not undergone splenectomy: alternative to IVIG → second-line treatment (persistent or chronic ITP): rituximab (anti-CD20) 375 mg/m² × 4 weeks: remission in 40–60% of patients + moderate durability + thrombopoietin receptor agonists (TPO-RA): eltrombopag (Revolade) PO or romiplostim (Nplate) SC → stimulate megakaryopoiesis → increase platelet production → efficacy 75–85% → long-term treatment + fostamatinib (SYK inhibitor) + avatrombopag → splenectomy: prolonged remission in 65–70% → effective if medical treatments fail → ITP treatment thresholds: routine treatment if platelets <20–30 × 10⁹/L or if significant bleeding regardless of count + pediatric ITP: often self-limiting (70–80% of patients recover spontaneously) → treat if severe bleeding + pregnancy-related ITP: IVIG + corticosteroids → avoid splenectomy if possible | Rodeghiero 2009 — Blood (ASH consensus) : ITP + definition + treatment → reference + Provan 2019 — Blood Advances (ASH guidelines update) : ITP + 2019 treatment + eltrombopag + romiplostim + Neunert 2011 — Blood (ASH guidelines) : pediatric ITP + adult + treatment + Kuter 2008 — NEJM (RAISE trial) : romiplostim + ITP → reference + Cheng 2011 — NEJM (EXTEND trial) : eltrombopag + ITP → reference + AHOQ (Association des hémato-oncologues du Québec) + INESSS Québec + RAMQ : prednisone + IVIG + rituximab + eltrombopag + romiplostim → reimbursed according to INESSS criteria |
| Constitutional thrombocytopathies and microangiopathies Bernard-Soulier giant platelets — GPIb-IX-V — ristocetin — MYH9 May-Hegglin — Döhle inclusions — genotyping — PTT SHU microangiopathy ADAMTS13 — schistocytes — HELLP — DIC — plasma exchange emergency — symptomatic treatment Bernard-Soulier compatible platelet transfusion |
Constitutional thrombocytopathies with megatrombocytes — diagnosis and management: Bernard-Soulier syndrome (BSS): autosomal recessive + mutations in GPIb-IX-V (ristocetin receptor complex + von Willebrand factor) → giant platelets (as large as red blood cells — «ghost» appearance on smear) + moderate thrombocytopenia (30–100 × 10⁹/L) + significantly prolonged bleeding time + absence of ristocetin-induced aggregation (but normal aggregation with ADP + collagen + epinephrine → distinguishes it from Glanzmann’s thrombasthenia, where aggregation is completely absent) → diagnosis: smear + bleeding time + platelet aggregation + flow cytometry (GPIb-IX absent) + genotyping → treatment: transfusion of normal platelets if severe bleeding → avoid aspirin + NSAIDs + desmopressin (DDAVP) sometimes useful → tranexamic acid + recombinant activated factor VII if surgery → MYH9 syndrome (May-Hegglin + Fechtner + Sebastian + Epstein): autosomal dominant + MYH9 gene mutation (non-muscle myosin IIa heavy chain) → giant platelets + grayish spindle-shaped inclusions in polymorphonuclear cells (pathological Döhle bodies → distinct from normal Döhle bodies seen in infections) → variable thrombocytopenia + sometimes hearing loss + nephritis + cataracts (depending on the syndrome) → diagnosis: smear (atypical Döhle bodies in PMNs ++) + MYH9 genotyping + thrombotic microangiopathy (TMA) with megathrombocytes: schistocytes +++ (erythrocyte fragments — sign of TMA) + thrombocytopenia + hemolytic anemia (very high LDH + collapsed haptoglobin) → PTT: ADAMTS13 <10 % → URGENT plasma exchanges → caplacizumab → HUS: Shiga toxin (E. coli O157:H7) or atypical HUS (alternative complement pathway mutation) → rituximab + eculizumab → HELLP: pregnancy → delivery + DIC → treatment of the underlying cause | Nurden 2008 — Haematologica: Bernard-Soulier syndrome + giant platelets + diagnosis → reference + Balduini 2011 — Haematologica: MYH9 + hereditary thrombocytopenias + genotyping + Harrison 2019 — British Journal of Haematology: hereditary thrombocytopenias + diagnosis → review + Scully 2019 — NEJM (HERCULES trial): caplacizumab + TTP → reference + Gresele 2014 — Platelets: macrothrombocytes + thrombocytopathies → AHOQ + INESSS Québec + RAMQ: genotyping + plasma exchange + caplacizumab → reimbursed according to criteria + hematologist mandatory for BSS or TTP |
ℹ️
Giant platelets on a blood smear indicate accelerated platelet production—their presence associated with thrombocytopenia suggests that the bone marrow is compensating for peripheral destruction, as in ITP or microangiopathies. Before interpreting thrombocytopenia with giant platelets, always rule out EDTA pseudothrombocytopenia (repeat the test using a citrate tube). The presence of schistocytes on the same smear should suggest a thrombotic microangiopathy (TTP + HUS) - a hematological emergency requiring immediate plasmapheresis.
Situations requiring urgent hematological care
Severe thrombocytopenia (<20 x 10⁹/L) + megathrombocytes + schistocytes on peripheral smear + very high LDH + absent haptoglobin + ± fever + ± neurological involvement → Thrombotic thrombocytopenic purpura (TTP) → absolute emergency → ADAMTS13 on an emergency basis → plasma exchange to be started within hours (without waiting for ADAMTS13 result if suggestive picture) → caplacizumab + methylprednisolone → hematologist on an emergency basis.
Severe thrombocytopenia (<10–20 × 10⁹/L) + giant platelets + active hemorrhage (mucosal + extensive purpura + gastrointestinal bleeding + intracranial hemorrhage) Severe hemorrhagic ITP → IVIG 1 g/kg + prednisone 1 mg/kg/day → or platelet transfusion if life-threatening hemorrhage (intracranial hemorrhage) → emergency hematologist → platelet count target >50 × 10⁹/L for urgent surgery + >100 × 10⁹/L if neurosurgery.
Patient with large platelets, atypical grayish inclusions in neutrophils (abnormal Döhle bodies), progressive bilateral hearing loss, and possibly proteinuria. → MYH9 syndrome (May-Hegglin or variant) → MYH9 genotyping + audiological assessment + renal assessment → no therapeutic urgency but specialized follow-up (hematologist + ENT specialist + nephrologist).
Consult at Clinique Omicron
Clinique Omicron physicians interpret blood smear results with macrothrombocytes in a clinical context, rule out EDTA pseudothrombocytopenia, prescribe appropriate etiological workup (LDH + haptoglobin + Coombs + anti-platelet antibodies + ADAMTS13 if schistocytes), recognize hematological emergencies (TTP + HUS + hemorrhagic ITP), initiate ITP treatment (prednisone + IVIG), and refer to a hematologist for complex or constitutional forms. Consultations are available at several service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for medical or hematological advice. Macrothrombocytes on a blood smear require specialized interpretation within their complete clinical context. Any severe thrombocytopenia associated with hemolysis and schistocytes is a hematological emergency.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.